Tag : ECZEMA

  • CONFERENCE UPDATE
    Impact of high-fat diet on skin microbiome in pediatric patients with food allergies and eczema

    Dysregulation of the human microbiome has been a common clinical feature observed in patients with atopic dermatitis (AD) and food allergy (FA). Since diet can lead to fluctuations in the microbiome, dietary modifications may serve as modulators for skin microbial composition.1 In mouse models, diets low in fatty acids have been associated with impairment in epithelial barrier functions. In addition, patients with both AD and FA have more severe epithelial barrier function impairment than those with AD only, further suggesting that dietary fat is essential for skin barrier function. Nevertheless, studies that investigated the efficacy of dietary modifications in the management of AD has been limited due to inconsistent outcomes and an incomplete understanding of the complex interactions behind the skin and gut microbiomes. During the 2024 AAAAI Annual Meeting, Dr. John Fyolek from Northwestern University Feinberg School of Medicine, the United States, shared the results of a study examining the effect of high-fat diets on skin microbiome in children with food allergies and eczema.

    doctor name

    Dr. Ho, Hok-Kung Marco

    Director, Lee Tak Hong Allergy Centre, Hong Kong Sanatorium & Hospital Honorary Clinical Associate Professor, Department of Paediatrics & Adolescent Medicine, The University of Hong Kong

  • NEWS AND PERSPECTIVE
    Dupilumab receives FDA approval for AD with moderate-to-severe hand and foot involvement based on data from the LIBERTY-AD-HAFT trial

    Despite being approved for the treatment of moderate-to-severe atopic dermatitis (AD), dupilumab’s efficacy in treating patients with atopic hand and foot dermatitis had not been evaluated. The LIBERTY-AD-HAFT trial demonstrated dupilumab’s efficacy and safety in treating patients with AD with moderate-to-severe hand and foot involvement. Based on the study results, the United States (US) Food and Drug Administration (FDA) updated the label of dupilumab to include AD with moderate-to-severe hand and foot involvement.